J. Moake, Thrombotic Microangiopathies, New England Journal of Medicine, vol.347, issue.8, p.589600, 2002.
DOI : 10.1056/NEJMra020528

W. Bell, H. Braine, P. Ness, and T. Kickler, Improved survival in thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Clinical experience in 108 patients, N Engl J Med. 8 août, vol.325, issue.6, p.398403, 1991.

F. Fakhouri, M. Hourmant, J. Campistol, S. Cataland, M. Espinosa et al., Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial, American Journal of Kidney Diseases, vol.68, issue.1, p.8493, 2016.
DOI : 10.1053/j.ajkd.2015.12.034

A. Froissart, M. Buffet, A. Veyradier, P. Poullin, F. Provôt et al., Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center, Critical Care Medicine, vol.40, issue.1, p.10411, 2012.
DOI : 10.1097/CCM.0b013e31822e9d66

F. Peyvandi, M. Scully, K. Hovinga, J. Cataland, S. Knöbl et al., Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura, New England Journal of Medicine, vol.374, issue.6, p.51122, 2016.
DOI : 10.1056/NEJMoa1505533

M. Scully, S. Cataland, P. Coppo, J. De-la-rubia, K. Friedman et al., Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies, Journal of Thrombosis and Haemostasis, vol.91, issue.Suppl. 1, p.31222, 2017.
DOI : 10.1097/MD.0b013e3182603598

E. Mariotte, E. Azoulay, L. Galicier, E. Rondeau, F. Zouiti et al., Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy, The Lancet Haematology, vol.3, issue.5, pp.237-245, 2016.
DOI : 10.1016/S2352-3026(16)30018-7

J. George and Z. Nouri, Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes, Hematol Am Soc Hematol Educ Program, vol.2012, p.6049, 2012.

J. Sadler, What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura, Hematology, vol.2015, issue.1, p.6316, 2015.
DOI : 10.1182/asheducation-2015.1.631

E. Moschcowitz, An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries; an undescribed disease, Am J Med. nov, vol.13, issue.5, p.5679, 1952.

J. Moake, C. Rudy, J. Troll, M. Weinstein, N. Colannino et al., Unusually Large Plasma Factor VIII: von Willebrand Factor Multimers in Chronic Relapsing Thrombotic Thrombocytopenic Purpura, New England Journal of Medicine, vol.307, issue.23, p.14325, 1982.
DOI : 10.1056/NEJM198212023072306

M. Furlan, R. Robles, and B. Lamie, Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis, Blood. 15 mai, vol.87, issue.10, p.422334, 1996.

M. Furlan, R. Robles, M. Solenthaler, M. Wassmer, P. Sandoz et al., Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura, Blood. 1 mai, vol.89, issue.9, p.3097103, 1997.

H. Tsai, Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion, Blood. 15 mai, vol.87, issue.10, p.423544, 1996.

M. Uemura, K. Tatsumi, M. Matsumoto, M. Fujimoto, T. Matsuyama et al., Localization of ADAMTS13 to the stellate cells of human liver, Blood, vol.106, issue.3, p.9224, 2005.
DOI : 10.1182/blood-2005-01-0152

L. Liu, H. Choi, A. Bernardo, A. Bergeron, L. Nolasco et al., Platelet-derived VWF-cleaving metalloprotease ADAMTS-13, Journal of Thrombosis and Haemostasis, vol.62, issue.11, p.253644, 2005.
DOI : 10.1074/jbc.M301385200

M. Manea, A. Kristoffersson, R. Schneppenheim, M. Saleem, P. Mathieson et al., Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura, British Journal of Haematology, vol.73, issue.5, p.65162, 2007.
DOI : 10.1038/labinvest.3700275

H. Tsai, Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura, Kidney International, vol.75, issue.112, pp.11-14, 2009.
DOI : 10.1038/ki.2008.610

Y. Asada, A. Sumiyoshi, T. Hayashi, J. Suzumiya, and K. Kaketani, Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen, Thrombosis Research, vol.38, issue.5, p.46979, 1985.
DOI : 10.1016/0049-3848(85)90180-X

A. Chauhan, M. Walsh, G. Zhu, D. Ginsburg, D. Wagner et al., The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis, Blood, vol.111, issue.7, p.34527, 2008.
DOI : 10.1182/blood-2007-08-108571

T. Ono, J. Mimuro, S. Madoiwa, K. Soejima, Y. Kashiwakura et al., Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure, Blood, vol.107, issue.2, p.52834, 2006.
DOI : 10.1182/blood-2005-03-1087

M. Uemura, Y. Fujimura, T. Matsuyama, M. Matsumoto, M. Ishikawa et al., Potential Role of ADAMTS13 in the Progression of Alcoholic Hepatitis, Current Drug Abuse Reviewse, vol.1, issue.2, p.18896, 2008.
DOI : 10.2174/1874473710801020188

A. Sánchez-luceros, C. Farías, M. Amaral, A. Kempfer, R. Votta et al., von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and postdelivery women, Thromb Haemost. déc, vol.92, issue.6, p.13206, 2004.

A. Lattuada, E. Rossi, C. Calzarossa, R. Candolfi, and P. Mannucci, Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome, Haematologica. sept, vol.88, issue.9, p.102934, 2003.

L. Lotta, I. Garagiola, R. Palla, A. Cairo, and F. Peyvandi, ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura, Hum Mutat. janv, vol.31, issue.1, p.119, 2010.

G. Levy, W. Nichols, E. Lian, T. Foroud, J. Mcclintick et al., Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura, Nature, vol.228, issue.6855, p.48894, 2001.
DOI : 10.1126/science.3874428

H. Tsai and E. Lian, Antibodies to von Willebrand Factor???Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura, New England Journal of Medicine, vol.339, issue.22, p.158594, 1998.
DOI : 10.1056/NEJM199811263392203

M. Furlan, R. Robles, M. Solenthaler, and B. Lämmle, Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura, Blood. 15 avr, vol.91, issue.8, p.283946, 1998.

M. Thomas, R. De-groot, M. Scully, and J. Crawley, Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura, EBioMedicine, vol.2, issue.8, p.94252, 2015.
DOI : 10.1016/j.ebiom.2015.06.007

S. Ferrari, K. Palavra, B. Gruber, K. Hovinga, J. Knöbl et al., Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura, Haematologica, vol.99, issue.4, p.77987, 2014.
DOI : 10.3324/haematol.2013.094151

S. Hirata, H. Okamoto, S. Ohta, T. Kobashigawa, M. Uesato et al., Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease, Rheumatology, vol.45, issue.8, p.10467, 2006.
DOI : 10.1093/rheumatology/kel176

J. Matsuda, T. Sanaka, K. Gohchi, K. Matsui, S. Uchida et al., Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus erythematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand factor-cleaving protease, Lupus, vol.11, issue.7, p.4634, 2002.

A. Schattner, J. Friedman, and A. Klepfish, Thrombotic thrombocytopenic purpura as an initial presentation of primary Sjögren's syndrome, Clin Rheumatol. févr, vol.21, issue.1, p.579, 2002.

D. Hart, R. Sayer, R. Miller, S. Edwards, A. Kelly et al., Human immunodeficiency virus associated thrombotic thrombocytopenic purpura - favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy, British Journal of Haematology, vol.142, issue.Suppl. 5, p.5159, 2011.
DOI : 10.1111/j.1365-2141.2008.07276.x

URL : https://hal.archives-ouvertes.fr/hal-00621304

E. Page, K. Hovinga, J. Terrell, D. Vesely, S. George et al., Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura, Blood, vol.128, issue.17, p.21758, 2016.
DOI : 10.1182/blood-2016-06-724161

P. Coppo, M. Busson, A. Veyradier, A. Wynckel, P. Poullin et al., HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians, Journal of Thrombosis and Haemostasis, vol.76, issue.4, p.8569, 2010.
DOI : 10.1111/j.1538-7836.2010.03772.x

M. Scully, J. Brown, R. Patel, V. Mcdonald, C. Brown et al., Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link, Journal of Thrombosis and Haemostasis, vol.112, issue.2, p.25762, 2010.
DOI : 10.1111/j.1538-7836.2009.03692.x

S. Martino, M. Jamme, C. Deligny, M. Busson, P. Loiseau et al., Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors, PLOS ONE, vol.121, issue.7, p.156679, 2016.
DOI : 10.1371/journal.pone.0156679.s001

URL : https://hal.archives-ouvertes.fr/hal-01347684

M. Morgand, M. Buffet, M. Busson, P. Loiseau, S. Malot et al., High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center, Transfusion, vol.86, issue.2, p.38997, 2014.
DOI : 10.1002/ajh.22091

URL : https://hal.archives-ouvertes.fr/hal-01064343

Y. Fujimura, M. Matsumoto, A. Isonishi, H. Yagi, K. Kokame et al., Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan, Journal of Thrombosis and Haemostasis, vol.92, issue.1, p.283301, 2011.
DOI : 10.1016/j.thromres.2006.07.012

S. Kinoshita, A. Yoshioka, Y. Park, H. Ishizashi, M. Konno et al., Upshaw-Schulman Syndrome Revisited: A Concept of Congenital Thrombotic Thrombocytopenic Purpura, International Journal of Hematology, vol.88, issue.1, p.1018, 2001.
DOI : 10.1111/j.1442-200X.1995.tb03697.x

Y. Delmas, S. Helou, P. Chabanier, A. Ryman, F. Pelluard et al., Incidence of obstetrical thrombotic thrombocytopenic purpura in a retrospective study within thrombocytopenic pregnant women. A difficult diagnosis and a treatable disease, BMC Pregnancy and Childbirth, vol.40, issue.1, p.137, 2015.
DOI : 10.1111/jog.12125

URL : https://hal.archives-ouvertes.fr/hal-01166878

Y. Benhamou, G. Paintaud, E. Azoulay, P. Poullin, L. Galicier et al., Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study, American Journal of Hematology, vol.83, issue.12, pp.1246-51, 2016.
DOI : 10.1097/01.md.0000133622.03370.07

M. Scully, V. Mcdonald, J. Cavenagh, B. Hunt, I. Longair et al., A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura, Blood, vol.118, issue.7, pp.1746-53, 2011.
DOI : 10.1182/blood-2011-03-341131

M. Soucemarianadin, Y. Benhamou, Y. Delmas, C. Pichereau, E. Maury et al., Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience, European Journal of Haematology, vol.8, issue.2, pp.183-91, 2016.
DOI : 10.1111/j.1538-7836.2010.03818.x

A. Ziman, M. Mitri, E. Klapper, S. Pepkowitz, and D. Goldfinger, Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature, Transfusion, vol.89, issue.1, pp.41-50, 2005.
DOI : 10.1182/blood-2002-05-1397

S. Cataland, J. M. Ferketich, A. Kennedy, M. Kraut, E. George et al., An evaluation of ciclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura, British Journal of Haematology, vol.93, issue.1, pp.146-155, 2007.
DOI : 10.1055/s-2005-925476

M. Kappers-klunne, P. Wijermans, R. Fijnheer, A. Croockewit, B. Van-der-holt et al., Splenectomy for the treatment of thrombotic thrombocytopenic purpura, British Journal of Haematology, vol.1, issue.5, pp.768-76, 2005.
DOI : 10.1182/blood-2003-11-4035

F. Beloncle, M. Buffet, J. Coindre, N. Munoz-bongrand, S. Malot et al., Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience, Transfusion, vol.48, issue.11, pp.2436-2480, 2012.
DOI : 10.1038/ki.2008.621

J. Chen, A. Reheman, F. Gushiken, L. Nolasco, X. Fu et al., N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice, Journal of Clinical Investigation, vol.121, issue.2, pp.593-603, 2011.
DOI : 10.1172/JCI41062DS1

G. Li, S. Rambally, J. Kamboj, S. Reilly, J. Moake et al., -acetylcysteine: a case report, Transfusion, vol.37, issue.5, pp.1221-1225, 2014.
DOI : 10.1097/CCM.0b013e31819ffed4

J. Shortt, D. Oh, and S. Opat, ADAMTS13 Antibody Depletion by Bortezomib in Thrombotic Thrombocytopenic Purpura, New England Journal of Medicine, vol.368, issue.1, pp.90-92, 2013.
DOI : 10.1056/NEJMc1213206

S. Park, H. Cheong, and J. Shin, Antibody Depletion by Bortezomib through Blocking of Antigen Presentation, New England Journal of Medicine, vol.368, issue.14, pp.1364-1369, 2013.
DOI : 10.1056/NEJMc1301264

B. Plaimauer, A. Schiviz, S. Kaufmann, W. Höllriegl, H. Rottensteiner et al., Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13, Journal of Thrombosis and Haemostasis, vol.67, issue.11, pp.2053-62, 2015.
DOI : 10.1097/MOH.0b013e328309ec62

C. Tersteeg, A. Schiviz, D. Meyer, S. Plaimauer, B. Scheiflinger et al., Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic PurpuraSignificance, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.35, issue.11, pp.2336-2378, 2015.
DOI : 10.1161/ATVBAHA.115.306014

C. Jian, X. J. Gong, L. Skipwith, C. Jin, S. Kwaan et al., Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood, pp.3836-3879, 2012.

J. Van-loon, P. De-jaegere, H. Ulrichts, H. Van-vliet, M. De-maat et al., The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention, Thrombosis and Haemostasis, vol.106, issue.1, pp.165-71, 2011.
DOI : 10.1160/TH10-12-0804

K. Hovinga, J. Vesely, S. Terrell, D. Lämmle, B. George et al., Survival and relapse in patients with thrombotic thrombocytopenic purpura, Blood, vol.115, issue.8, pp.1500-1511, 2010.
DOI : 10.1182/blood-2009-09-243790

F. Peyvandi, S. Lavoretano, R. Palla, H. Feys, K. Vanhoorelbeke et al., ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission, Haematologica, vol.93, issue.2, pp.232-241, 2008.
DOI : 10.3324/haematol.11739

M. Hie, J. Gay, L. Galicier, F. Provôt, C. Presne et al., Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura, Blood, vol.124, issue.2, pp.204-214, 2014.
DOI : 10.1182/blood-2014-01-550244

Y. Benhamou, C. Assié, P. Boelle, M. Buffet, R. Grillberger et al., Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience, Haematologica, vol.97, issue.8, pp.1181-1187, 2012.
DOI : 10.3324/haematol.2011.049676

URL : https://hal.archives-ouvertes.fr/inserm-00700485

P. Coppo, M. Wolf, A. Veyradier, A. Bussel, S. Malot et al., Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura, British Journal of Haematology, vol.138, issue.1, pp.66-74, 2006.
DOI : 10.1182/blood-2003-11-4035

URL : https://hal.archives-ouvertes.fr/hal-00453285

C. Deford, J. Reese, L. Schwartz, J. Perdue, K. Hovinga et al., Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood, pp.2023-2029, 2013.

M. Roriz, M. Landais, J. Desprez, C. Barbet, E. Azoulay et al., Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura, Medicine, vol.94, issue.42, p.1598, 2015.
DOI : 10.1097/MD.0000000000001598

P. Ruggenenti, M. Noris, and G. Remuzzi, Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura, Kidney International, vol.60, issue.3, pp.831-877, 2001.
DOI : 10.1046/j.1523-1755.2001.060003831.x

S. Javett and B. Senior, Syndrome of hemolysis, thrombopenia and nephropathy in infancy, Pediatrics. févr, vol.29, pp.209-232, 1962.

L. Riley, R. Remis, S. Helgerson, H. Mcgee, J. Wells et al., HEMORRHAGIC COLITIS ASSOCIATED WITH A RARE ESCHERICHIA COLI SEROTYPE., The Pediatric Infectious Disease Journal, vol.2, issue.4, pp.681-686, 1983.
DOI : 10.1097/00006454-198307000-00031

M. Karmali, B. Steele, M. Petric, and C. Lim, SPORADIC CASES OF HAEMOLYTIC-URAEMIC SYNDROME ASSOCIATED WITH FAECAL CYTOTOXIN AND CYTOTOXIN-PRODUCING ESCHERICHIA COLI IN STOOLS, The Lancet, vol.321, issue.8325, pp.619-639, 1983.
DOI : 10.1016/S0140-6736(83)91795-6

P. Tarr, C. Gordon, and W. Chandler, Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome, The Lancet, vol.365, issue.9464, pp.1073-86, 2005.
DOI : 10.1016/S0140-6736(05)71144-2

P. Ruggenenti and G. Remuzzi, A German outbreak of haemolytic uraemic syndrome, The Lancet, vol.378, issue.9796, pp.1057-1065, 2011.
DOI : 10.1016/S0140-6736(11)61217-8

Y. Delmas, B. Vendrely, B. Clouzeau, H. Bachir, H. Bui et al., Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab, Nephrology Dialysis Transplantation, vol.29, issue.3, pp.565-72, 2014.
DOI : 10.1093/ndt/gft470

A. Constantinescu, M. Bitzan, L. Weiss, C. E. Kaplan, B. Cnaan et al., Non-enteropathic hemolytic uremic syndrome: causes and short-term course, American Journal of Kidney Diseases, vol.43, issue.6, pp.976-82, 2004.
DOI : 10.1053/j.ajkd.2004.02.010

D. Wittenberg, Emerging and re-emerging diseases--epidemic enterohaemorrhagic infections 100 years after Shiga. South Afr Med J Suid-Afr Tydskr Vir Geneeskd, juill, vol.89, issue.7, pp.750-752, 1999.

B. Aldabe, Y. Delmas, G. Gault, B. Vendrely, B. Llanas et al., Household transmission of haemolytic uraemic syndrome associated with Escherichia coli O104:H4, south-western France, Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 4 août, vol.16, issue.31, 2011.
URL : https://hal.archives-ouvertes.fr/pasteur-01121005

V. Tesh, The Induction of Apoptosis by Shiga Toxins and Ricin, Curr Top Microbiol Immunol, vol.357, pp.137-78, 2012.
DOI : 10.1007/82_2011_155

D. Karpman and A. Ståhl, Enterohemorrhagic Escherichia coli Pathogenesis and the Host Response, Microbiology Spectrum, vol.2, issue.5, 2014.
DOI : 10.1128/microbiolspec.EHEC-0009-2013

A. Ståhl, I. Arvidsson, K. Johansson, M. Chromek, J. Rebetz et al., A Novel Mechanism of Bacterial Toxin Transfer within Host Blood Cell-Derived Microvesicles, PLOS Pathogens, vol.12, issue.2, p.1004619, 2015.
DOI : 10.1371/journal.ppat.1004619.s004

J. Huang, D. Motto, D. Bundle, and J. Sadler, Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice, Blood, vol.116, issue.18, pp.3653-3662, 2010.
DOI : 10.1182/blood-2010-02-271957

M. Noris and G. Remuzzi, Hemolytic Uremic Syndrome, Journal of the American Society of Nephrology, vol.16, issue.4, pp.1035-50, 2005.
DOI : 10.1681/ASN.2004100861

C. Wong, S. Jelacic, R. Habeeb, S. Watkins, and P. Tarr, O157:H7 Infections, New England Journal of Medicine, vol.342, issue.26, pp.1930-1936, 2000.
DOI : 10.1056/NEJM200006293422601

M. Nitschke, F. Sayk, C. Härtel, R. Roseland, S. Hauswaldt et al., Association Between Azithromycin Therapy and Duration of Bacterial Shedding Among Patients With Shiga Toxin???Producing Enteroaggregative Escherichia coli O104:H4, JAMA, vol.307, issue.10, pp.1046-52, 2012.
DOI : 10.1001/jama.2012.264

C. Karpac, X. Li, D. Terrell, K. Hovinga, J. Lämmle et al., Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison, British Journal of Haematology, vol.71, issue.5, pp.696-707, 2008.
DOI : 10.1056/NEJM200006293422601

J. Kielstein, G. Beutel, S. Fleig, J. Steinhoff, T. Meyer et al., Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic???uraemic syndrome: an analysis of the German STEC-HUS registry, Nephrology Dialysis Transplantation, vol.27, issue.10, pp.3807-3822, 2012.
DOI : 10.1093/ndt/gfs394

A. Greinacher, S. Friesecke, P. Abel, A. Dressel, S. Stracke et al., Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial, The Lancet, vol.378, issue.9797, pp.1166-73, 2011.
DOI : 10.1016/S0140-6736(11)61253-1

C. Combe, H. Bui, V. De-précigout, G. Hilbert, and Y. Delmas, Immunoadsorption in patients with haemolytic uraemic syndrome, The Lancet, vol.379, issue.9815, pp.517-518, 2012.
DOI : 10.1016/S0140-6736(12)60228-1

A. Lapeyraque, M. Malina, V. Fremeaux-bacchi, T. Boppel, M. Kirschfink et al., Eculizumab in Severe Shiga-Toxin???Associated HUS, New England Journal of Medicine, vol.364, issue.26, pp.2561-2564, 2011.
DOI : 10.1056/NEJMc1100859

D. Karpman and R. Tati, Complement contributes to the??pathogenesis of Shiga toxin???associated hemolytic uremic syndrome, Kidney International, vol.90, issue.4, pp.726-735, 2016.
DOI : 10.1016/j.kint.2016.07.002

A. Rosales, J. Hofer, L. Zimmerhackl, T. Jungraithmayr, M. Riedl et al., Need for Long-term Follow-up in Enterohemorrhagic Escherichia coli???Associated Hemolytic Uremic Syndrome Due to Late-Emerging Sequelae, Clinical Infectious Diseases, vol.54, issue.10, pp.1413-1434, 2012.
DOI : 10.1093/cid/cis196

M. Farr, S. Roberts, A. Morley, D. Dewar, and P. Uldall, The haemolytic uraemic syndrome--a family study, Q J Med. avr, vol.44, issue.174, pp.161-88, 1975.

B. Kaplan, R. Chesney, and K. Drummond, Hemolytic Uremic Syndrome in Families, New England Journal of Medicine, vol.292, issue.21, pp.1090-1093, 1975.
DOI : 10.1056/NEJM197505222922102

R. Thompson and M. Winterborn, Hypocomplementaemia due to a genetic deficiency of beta 1H globulin, Clin Exp Immunol. oct, vol.46, issue.1, pp.110-119, 1981.

P. Warwicker, T. Goodship, R. Donne, Y. Pirson, A. Nicholls et al., Genetic studies into inherited and sporadic hemolytic uremic syndrome, Kidney International, vol.53, issue.4, pp.836-880, 1998.
DOI : 10.1111/j.1523-1755.1998.00824.x

N. Merle, S. Church, V. Fremeaux-bacchi, and L. Roumenina, Complement System Part I ???????? Molecular Mechanisms of Activation and Regulation, Frontiers in Immunology, vol.703, issue.181, p.262, 2015.
DOI : 10.1007/978-1-4419-5635-4_10

M. Dragon-durey and V. Frémeaux-bacchi, Atypical haemolytic uraemic syndrome and mutations in complement regulator genes, Springer Seminars in Immunopathology, vol.78, issue.11, pp.359-74, 2005.
DOI : 10.4049/jimmunol.169.4.2102

M. Noris and G. Remuzzi, Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015, American Journal of Kidney Diseases, vol.66, issue.2, pp.359-75, 2015.
DOI : 10.1053/j.ajkd.2015.03.040

A. Sellier-leclerc, V. Fremeaux-bacchi, M. Dragon-durey, M. Macher, P. Niaudet et al., Differential Impact of Complement Mutations on Clinical Characteristics in Atypical Hemolytic Uremic Syndrome, Journal of the American Society of Nephrology, vol.18, issue.8, pp.2392-400, 2007.
DOI : 10.1681/ASN.2006080811

URL : https://hal.archives-ouvertes.fr/inserm-00409786

M. Noris, J. Caprioli, E. Bresin, C. Mossali, G. Pianetti et al., Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype, Clinical Journal of the American Society of Nephrology, vol.5, issue.10, pp.1844-59, 2010.
DOI : 10.2215/CJN.02210310

J. Caprioli, M. Noris, S. Brioschi, G. Pianetti, F. Castelletti et al., Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome, Blood, vol.108, issue.4, pp.1267-79, 2006.
DOI : 10.1182/blood-2005-10-007252

F. Fakhouri, L. Roumenina, F. Provot, M. Sallée, S. Caillard et al., Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations, Journal of the American Society of Nephrology, vol.21, issue.5, pp.859-67, 2010.
DOI : 10.1681/ASN.2009070706

URL : https://hal.archives-ouvertes.fr/hal-00512540

C. Loirat and V. Frémeaux-bacchi, Atypical hemolytic uremic syndrome, Orphanet Journal of Rare Diseases, vol.6, issue.1, p.60, 2011.
DOI : 10.1007/s00467-010-1608-9

URL : https://hal.archives-ouvertes.fr/hal-01064383

M. Dragon-durey, S. Sethi, A. Bagga, C. Blanc, J. Blouin et al., Clinical Features of Anti-Factor H Autoantibody-Associated Hemolytic Uremic Syndrome, Journal of the American Society of Nephrology, vol.21, issue.12, pp.2180-2187, 2010.
DOI : 10.1681/ASN.2010030315

G. Remuzzi, R. Misiani, D. Marchesi, M. Livio, G. Mecca et al., Treatment of the hemolytic uremic syndrome with plasma, Clin Nephrol. déc, vol.12, issue.6, pp.279-84, 1979.

C. Legendre, C. Licht, P. Muus, L. Greenbaum, S. Babu et al., Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic???Uremic Syndrome, New England Journal of Medicine, vol.368, issue.23, pp.2169-81, 2013.
DOI : 10.1056/NEJMoa1208981

R. Brodsky, Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria, Blood Reviews, vol.22, issue.2, pp.65-74, 2008.
DOI : 10.1016/j.blre.2007.10.002

A. Servais, N. Devillard, V. Frémeaux-bacchi, A. Hummel, L. Salomon et al., Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab, Nephrology Dialysis Transplantation, vol.31, issue.12, pp.2122-2152, 2016.
DOI : 10.1093/ndt/gfw314

Y. Delmas, C. Bordes, C. Loirat, V. Frémeaux-bacchi, and C. Combe, Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice, Clinical Kidney Journal, vol.6, issue.2, pp.243-247, 2013.
DOI : 10.1093/ckj/sfs185

J. Nishimura, M. Yamamoto, S. Hayashi, K. Ohyashiki, K. Ando et al., Genetic Variants in C5 and Poor Response to Eculizumab, New England Journal of Medicine, vol.370, issue.7, pp.632-641, 2014.
DOI : 10.1056/NEJMoa1311084

E. Goicoechea-de-jorge, C. Harris, J. Esparza-gordillo, L. Carreras, E. Arranz et al., Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome, Proceedings of the National Academy of Sciences, vol.277, issue.2, pp.240-245, 2007.
DOI : 10.1074/jbc.M109322200

J. Zuber, L. Quintrec, M. Krid, S. Bertoye, C. Gueutin et al., Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation, American Journal of Transplantation, vol.1, issue.12, pp.3337-54, 2012.
DOI : 10.1111/j.1365-2141.2009.07916.x

F. Fakhouri, J. Zuber, V. Frémeaux-bacchi, and C. Loirat, Haemolytic uraemic syndrome, The Lancet, vol.390, issue.10095, 2017.
DOI : 10.1016/S0140-6736(17)30062-4

J. George, C. Nester, and J. Mcintosh, Syndromes of thrombotic microangiopathy associated with pregnancy, Hematology, vol.2015, issue.1, pp.644-652, 2015.
DOI : 10.1182/asheducation-2015.1.644

M. Frimat, M. Decambron, C. Lebas, A. Moktefi, L. Lemaitre et al., Renal Cortical Necrosis in Postpartum Hemorrhage: A Case Series, American Journal of Kidney Diseases, vol.68, issue.1, pp.50-57, 2016.
DOI : 10.1053/j.ajkd.2015.11.022

Z. Al-nouri, J. Reese, D. Terrell, S. Vesely, and J. George, Drug-induced thrombotic microangiopathy: a systematic review of published reports, Blood, vol.125, issue.4, pp.616-624, 2015.
DOI : 10.1182/blood-2014-11-611335

B. Van-den-born, N. Van-der-hoeven, E. Groot, P. Lenting, J. Meijers et al., Association Between Thrombotic Microangiopathy and Reduced ADAMTS13 Activity in Malignant Hypertension, Hypertension, vol.51, issue.4, pp.862-868, 1979.
DOI : 10.1161/HYPERTENSIONAHA.107.103127

S. Timmermans, M. Abdul-hamid, J. Vanderlocht, J. Damoiseaux, C. Reutelingsperger et al., Patients with hypertension-associated thrombotic??microangiopathy may present with??complement abnormalities, Kidney International, vol.91, issue.6, 2017.
DOI : 10.1016/j.kint.2016.12.009

L. Mouthon, A. Bérezné, G. Bussone, L. Noël, P. Villiger et al., Scleroderma Renal Crisis: A Rare but Severe Complication of Systemic Sclerosis, Clinical Reviews in Allergy & Immunology, vol.66, issue.7, pp.84-91, 2011.
DOI : 10.1136/ard.2006.066068

J. Morton and J. George, Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer, Journal of Oncology Practice, vol.12, issue.6, pp.523-553, 2016.
DOI : 10.1200/JOP.2016.012096

G. Favre, M. Touzot, V. Fremeaux-bacchi, H. Hyvernat, J. Gueffet et al., Malignancy and thrombotic microangiopathy or atypical haemolytic and uraemic syndrome?, British Journal of Haematology, vol.8, issue.5, pp.802-807, 2014.
DOI : 10.1038/nrneph.2012.214

T. Ruutu, G. Barosi, R. Benjamin, R. Clark, J. George et al., Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group, Haematologica, vol.92, issue.1, pp.95-100, 2007.
DOI : 10.3324/haematol.10699

C. Gall, E. Delmas, Y. , D. Parscau, L. Doucet et al., Adult-Onset Eculizumab-Resistant Hemolytic Uremic Syndrome Associated With Cobalamin C Deficiency, American Journal of Kidney Diseases, vol.63, issue.1, pp.119-142, 2014.
DOI : 10.1053/j.ajkd.2013.08.031

URL : https://hal.archives-ouvertes.fr/hal-01011789

K. Swisher, J. Doan, S. Vesely, H. Kwaan, B. Kim et al., Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports, Haematologica, vol.92, issue.7, pp.936-979, 2007.
DOI : 10.3324/haematol.10963

J. Routh and S. Koenig, Severe vitamin B12 deficiency mimicking thrombotic thrombocytopenic purpura, Blood, vol.124, issue.11, p.1844, 2014.
DOI : 10.1182/blood-2014-03-562488

S. Hartong, E. A. Steegers, and W. Visser, Hemolysis, elevated liver enzymes and low platelets during pregnancy due to Vitamin B12 and folate deficiencies, European Journal of Obstetrics & Gynecology and Reproductive Biology, vol.131, issue.2, pp.241-243, 2007.
DOI : 10.1016/j.ejogrb.2006.04.026

J. George, The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, Kidney Int Suppl. févr, issue.112, pp.52-54, 1989.

J. Sadler, Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura, Blood, vol.112, issue.1, pp.11-19, 2008.
DOI : 10.1182/blood-2008-02-078170

P. Coppo, D. Bengoufa, A. Veyradier, M. Wolf, A. Bussel et al., Severe ADAMTS13 Deficiency in Adult Idiopathic Thrombotic Microangiopathies Defines a Subset of Patients Characterized by Various Autoimmune Manifestations, Lower Platelet Count, and Mild Renal Involvement, Medicine, vol.83, issue.4, pp.233-277, 2004.
DOI : 10.1097/01.md.0000133622.03370.07

F. Fakhouri, M. Fila, F. Provôt, Y. Delmas, C. Barbet et al., Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation, Clinical Journal of the American Society of Nephrology, vol.12, issue.1, pp.50-59, 2017.
DOI : 10.2215/CJN.06440616

J. Harambat, D. Lamireau, Y. Delmas, A. Ryman, B. Llanas et al., Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: a pediatric report and literature review. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc, mars, vol.12, issue.2, pp.90-93, 2011.

M. Jang, S. Chong, I. Kim, J. Kim, C. Jung et al., Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience, International Journal of Hematology, vol.93, issue.Suppl 2, pp.163-172, 2011.
DOI : 10.3324/haematol.11739

Y. Fujimura and M. Matsumoto, Registry of 919 Patients with Thrombotic Microangiopathies across Japan: Database of Nara Medical University during 1998-2008, Internal Medicine, vol.49, issue.1, pp.7-15, 2010.
DOI : 10.2169/internalmedicine.49.2706

V. Fremeaux-bacchi, F. Fakhouri, A. Garnier, F. Bienaimé, M. Dragon-durey et al., Genetics and Outcome of Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children and Adults, Clinical Journal of the American Society of Nephrology, vol.8, issue.4, pp.554-62, 2013.
DOI : 10.2215/CJN.04760512

. Méthodes, Nous avons inclus rétrospectivement tous les patients âgés de plus de 15 ans et 3

. Résultats, Parmi les 94 patients inclus, 42,5% avaient un PTT acquis et 18, p.1

P. Le and . Significativement-associé-À-moins-d-'atteinte-rénale-sévère, 5%) et à plus d'atteinte neurologique (31%) Parmi eux, 50% ont reçu un traitement immunosuppresseur en première ligne et 32,5% en traitement d'entretien, associé à seulement 9,4% de rechute clinique mais un taux de mortalité élevé de 20%. Le CM-HUS était significativement associé à plus d'atteinte rénale sévère (70.6%) Parmi eux, 76,5% ont reçu de l'Eculizumab, associé à un taux de rechute clinique de 30% mais seulement 7,1% d'insuffisance rénale chronique stade V à la fin du suivi